Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis

A Phase Ib/IIa, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral Treatment With OST-122 in Patients With Moderate to Severe Ulcerative Colitis

A Phase Ib/IIa to evaluate the safety and tolerability of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis over 28 days. This trial will also explore pharmacokinetics (PK) profile and preliminary therapeutic efficacy associated with OST-122 through biomarker analysis and clinical, endoscopic and histologic assessments.

Study Overview

• Status: Completed
• Conditions: Ulcerative Colitis Chronic Moderate; Ulcerative Colitis Chronic Severe
• Intervention / Treatment: Drug: Placebo; Drug: OST-122

Detailed Description

OST-122 is an oral, gut-restricted and subtype-selective Jak3/Tyk2/Ark5 inhibitor for the local treatment of inflammatory bowel disease (IBD) including ulcerative colitis, Crohn's disease and, potentially, fibrotic lesions in Crohn's patients. The compound was well tolerated in a Phase 1 study in healthy volunteers and has been shown to be stable during the GI transit, while no significant plasma levels were detected. The gut-restricted PK profile of OST-122 lowers the risk of systemic toxicities inherent to other JAK inhibitors. In the current proof of concept study, the compound's safety, PK profile and trends of efficacy will be investigated in patients with moderate to severe ulcerative colitis.

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Spain
  • Barcelona, Spain
    • Hospital de la Santa Creu i Sant Pau
  • Córdoba, Spain
    • Hospital Reina Sofia
  • Girona, Spain, 17007
    • Hospital Universitari Doctor Josep Trueta
  • Huesca, Spain
    • Hospital San Jorge
  • Madrid, Spain
    • Hospital Universitario La Paz
  • Madrid, Spain
    • Hospital Infanta Leonor
  • Oviedo, Spain
    • Hospital Universitario Central de Asturias
  • Sevilla, Spain, 41009
    • Hospital Universitario Virgen Macarena
  • Zaragoza, Spain
    • Hospital Universitario Miguel Servet
  • Zaragoza, Spain
    • Hospital Clinico Universitario Lozano Blesa
  • A Coruña
    • Santiago de Compostela, A Coruña, Spain
      • Complejo Hospitalario Universitario de Santiago
  • Madrid
    • Alcorcón, Madrid, Spain
      • Hospital Universitario Fundación Alcorcón
  • Navarra
    • Pamplona, Navarra, Spain
      • Complejo Hospitalario de Navarra
  • Pontevedra
    • Vigo, Pontevedra, Spain
      • Hospital Álvaro Cunqueiro
• Ukraine
  • Kropyvnytskyi, Ukraine
    • Medical and Diagnostic Center PE PMC "Acinus"
  • Kyiv, Ukraine
    • Medical Center "Ok!Clinic" of International Institute of Clinical Research LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Willing and able to provide written informed consent and capable of understanding and complying with the protocol;
2. Patients male and female ≥ 18 and ≤ 75 years at the time of consent;
3. Patient with previous diagnosis of ulcerative colitis: ulcerative proctitis, left-side ulcerative colitis or extensive/pancolitis (E1, E2 and E3 of Montreal Classification, respectively) established at least 3 months prior to screening and determined by standard clinical, endoscopic, and histological procedures;
4. Demonstrated inadequate response, loss of response, or intolerance to at least one of the following treatments including, aminosalicylates (ASAs), corticosteroids, immunosuppressants, anti-tumor necrosis factor (TNF)-α agents, integrin inhibitor or anti interleukin 12/23;
5. If the subject is currently receiving an oral aminosalicylate, he or she is eligible and can stay on that dose of aminosalicylate provided the dose has been stable for at least 1 week prior to screening;
6. If the subject is currently receiving an oral corticosteroid, he or she is eligible if the dose is equivalent to or less than prednisone 20 mg/day or beclomethasone dipropionate 5 mg/day and stable for at least 1 week prior to Screening visit;
7. Has an endoscopic Mayo subscore of ≥ 2 and a total Mayo score of 5-10 during screening;
8. Women who are not postmenopausal (at least 12 months) or surgically sterile must have a negative pregnancy test at screening and at the end of study and either abstain from sexual intercourse or use a highly effective method of birth control (double barrier) for the duration of the study and after 12 weeks after the last dose of study drug;
9. For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm for the duration of the study and after 12 weeks from the last dose of study drug;
10. Availability for the entire study period, absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; willingness to adhere to the protocol requirements, ability to cooperate adequately and to understand and follow the instructions of the physician or designee.

Exclusion Criteria:

1. Has fulminant colitis, toxic megacolon, primary sclerosing cholangitis, Crohn's disease, history of moderate to severe colitis-associated colonic dysplasia, active peptic ulcer disease;

2. Medications of exclusion:

   1. Topical mesalazine or steroids (i.e., enemas or suppositories) within the 7 days prior to Baseline visit
   2. Azathioprine, 6-mercaptopurine, or methotrexate within 10 days prior to Baseline visit
   3. Intravenous corticosteroids within the 14 days prior to Baseline visit
   4. Tofacitinib or any other JAK inhibitor within 14 days prior to Baseline visit
   5. Anti-diarrheal treatment within 14 days prior to Baseline visit
   6. Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 14 days prior to Baseline visit
   7. Adalimumab within the 14 days prior to Baseline visit
   8. Infliximab, golimumab, etanercept, vedolizumab, ustekinumab or certolizumab within the 14 days prior to Baseline visit
   9. NSAIDs on a daily basis from 7 days previous to Baseline visit. Low doses, without anti-inflammatory effect, to treat or prevent other diseases i.e.: ictus, cerebrovascular or cardiovascular diseases, among others; are permitted.
3. Has a current bacterial, parasitic, fungal, or viral infection;
4. Is positive for hepatitis A, B or C, HIV (Human Immunodeficiency Virus) or tuberculosis, as assessed by method available at each site;
5. Patient who has clinically significant diseases and/or infections captured in the medical history or evidence of clinically significant findings on physical examination and/or clinically significant ordinary laboratory evaluations (haematology, biochemistry, and urinalysis) or ECG;
6. Participated in another clinical trial of an investigational drug (or medical device) within 30 days prior to Baseline (or within 60 days prior to Baseline if investigational drug was a biologic product);
7. Demonstrated an inadequate response or loss of response to Tofacitinib or any other JAK inhibitor, with the exception of those patients who after a careful evaluation, the PI considers they may obtain a clinical benefit from the therapy;
8. Use of products, food supplements or medical devices, whose composition includes probiotics in the 1 month prior to Baseline visit;
9. Patient who has prior extensive colonic resection, subtotal or total colectomy or planned surgery for ulcerative colitis;
10. Patient who has past or present fistula or abdominal abscess;
11. Patient who is pregnant or lactating;
12. Inability to comply with study protocol, in opinion of the investigator;
13. History of alcohol, drug or chemical abuse within 6 months prior to Screening visit;
14. History of cancer within the last 5 years. Patients with local basal or squamous cell carcinoma of the skin that has been excised and is considered cured may be included.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Experimental arm OST-122; 24 subjects will be randomized to receive OST-122 orally daily for 28 days	Drug: OST-122; Active dose
Placebo Comparator: Control arm Placebo; 8 subjects will be randomized to receive placebo orally daily for 28 days	Drug: Placebo; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the safety of OST-122 administered for 28 days in subjects with active UC by assessing the number, severity, and type of adverse events	Number and severity of AEs reported including Clinically Significant Changes in vital signs, physical examination, Laboratory Measurements, and ECGs.	From baseline to end of the follow-up period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax: Maximum plasma concentration for OST-122	Pharmacokinetic analysis of OST-122 peak concentration in plasma (ng/ml) in every subject enrolled in this trial	Day 1 and Day 28
Ctrough: Minimum plasma concentration for OST-122	Pharmacokinetic analysis of OST-122 minimum concentration in plasma (ng/ml) in every subject enrolled in this trial	Day 1 and Day 28
Percentage of subjects with improvement in Endoscopic Mayo Score	Study the effect of OST-122 or placebo in Endoscopic Mayo Score Subjects (%) with improvement of endoscopy subscore by ≥1 point Subjects (%) with endoscopy subscore of 0-1	Day 0 and Day 28
Percentage of subjects with improvement in PRO-2	Study the effect of OST-122 or placebo in PRO-2 [PRO-2: sum of the scores obtained in rectal bleeding and stool frequency (subscores 1+2 of the Mayo Score)] Subjects (%) with PRO-2 subscore of 0-1 Subjects (%) with improvement of PRO-2 subscore by ≥1 point Subjects (%) with improvement of rectal bleeding subscore by ≥1 point Subjects (%) with rectal bleeding subscore of 0-1 Subjects (%) with improvement of stool frequency subscore by ≥1 point Subjects (%) with stool frequency subscore of 0-1	Day 0, Day 7, Day 14, Day 21, Day 28
Study the effect of OST-122 or placebo on faecal calprotectin levels	Change from baseline of faecal calprotectin (mg/kg) compared to placebo	Day 1, Day 7, Day 14, Day 21, Day 28
Effect of OST-122 or placebo on serum C-reactive protein levels	Change from baseline of serum C-reactive protein (mg/L) compared to placebo	Day 0, Day 14, Day 28
Tmax: Time to reach maximum plasma concentration (Cmax) for OST-122	Pharmacokinetic analysis of OST-122 time (in hours) needed for OST-122 to reach the Cmax (peak concentration) in every subject enrolled in this trial	Day 1 and Day 28
AUC: Area under the plasma-concentration time-curve	Pharmacokinetic analysis of OST-122 observed area under the plasma-concentration time-curve (ng · h / ml) in every subject enrolled in this trial	Day 1 and Day 28

Collaborators and Investigators

• Sponsor: Oncostellae S.L
• Investigators: Study Director: Ascensión Heredia Rodríguez, PhD, Oncostellae S.L

Study record dates

Study Major Dates

• Study Start (Actual): September 16, 2020
• Primary Completion (Actual): December 27, 2022
• Study Completion (Actual): December 27, 2022

Study Registration Dates

• First Submitted: March 24, 2020
• First Submitted That Met QC Criteria: April 17, 2020
• First Posted (Actual): April 20, 2020

Study Record Updates

• Last Update Posted (Estimate): January 13, 2023
• Last Update Submitted That Met QC Criteria: January 11, 2023
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Gastrointestinal Diseases; Gastroenteritis; Colonic Diseases; Intestinal Diseases; Inflammatory Bowel Diseases; Ulcer; Colitis; Colitis, Ulcerative
• Other Study ID Numbers: CT-OST-122-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No